

Zai Lab to Host Virtual Research and Development Day on September 22, 2021

September 9, 2021

- Event to be webcast on Wednesday, September 22 at 8:30 a.m. EDT -

SHANGHAI and SAN FRANCISCO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced it will host a Virtual R&D Day for analysts and investors on September 22, 2021. The webcast will take place from 8:30 a.m. EDT to approximately 11:30 a.m. EDT, followed by a 30-minute live Q&A session.

Registration Information of Zai Lab R&D Day Webcast and Live Q&A Session

All participants must register in advance of the webcast and conference call. For the webcast, upon registering, each participant will receive an email with login information. For the Q&A conference call, upon registering, each participant will receive a dial-in number, Direct Event passcode, and a unique access PIN, which can be used to join the conference call. Details are as follows:

Registration Link for the Webcast: https://apac.onlinexperiences.com/Launch/QReg/ShowUUID=6C460A8F-06BE-4BAC-8145-50F96BBD788E

Registration Link for Live Q&A: <u>https://apac.directeventreg.com/registration/event/2966248</u>

Conference ID for Live Q&A: 2966248

An archived replay will be available shortly after the webcast has concluded.

About Zai Lab

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company focused on developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders and infectious disease. To that end, our experienced team has secured partnerships with leading global biopharmaceutical companies in order to generate a broad pipeline of innovative marketed products and product candidates. We have also built an in-house team with strong product discovery and translational research capabilities and are establishing a pipeline of proprietary product candidates with global rights. Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing and commercializing our portfolio in order to impact human health worldwide.

For additional information about the company, please visit www.zailaboratory.com or follow us at www.twitter.com/Zail.ab_Global.

For more information, please contact:

ZAI LAB CONTACTS:

Zai Lab Billy Cho, CFO +86 137 6151 2501 billy.cho@zailaboratory.com

Media: Ryo Imai / Robert Flamm, Ph.D. Burns McClellan, on behalf of Zai Lab 212-213-0006 ext. 315 / 364 rimai@burnsmc.com / rflamm@burnsmc.com

Investors: Mike Zanoni Endurance Advisors, on behalf of Zai Lab 610-442-8570 mzanoni@enduranceadvisors.com

Zai Lab Limited



Source: Zai Lab Limited